Research ExplorerPublicationsTranscatheter aortic valve-in-valve implantation in degenera...

Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses

Standard

Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses. / Landes, Uri; Dvir, Danny; Schoels, Wolfgang; Tron, Christopher; Ensminger, Stephan; Simonato, Matheus; Schäfer, Ulrich; Bunc, Matjaz; Aldea, Gabriel S; Cerillo, Alfredo; Windecker, Stephan; Marzocchi, Antonio; Andreas, Martin; Amabile, Nicolas; Webb, John; Kornowski, Ran.

In: EUROINTERVENTION, Vol. 15, No. 1, 20.05.2019, p. 37-43.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Landes, U, Dvir, D, Schoels, W, Tron, C, Ensminger, S, Simonato, M, Schäfer, U, Bunc, M, Aldea, GS, Cerillo, A, Windecker, S, Marzocchi, A, Andreas, M, Amabile, N, Webb, J & Kornowski, R 2019, 'Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses', EUROINTERVENTION, vol. 15, no. 1, pp. 37-43. https://doi.org/10.4244/EIJ-D-18-00752

APA

Landes, U., Dvir, D., Schoels, W., Tron, C., Ensminger, S., Simonato, M., Schäfer, U., Bunc, M., Aldea, G. S., Cerillo, A., Windecker, S., Marzocchi, A., Andreas, M., Amabile, N., Webb, J., & Kornowski, R. (2019). Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses. EUROINTERVENTION, 15(1), 37-43. https://doi.org/10.4244/EIJ-D-18-00752

Vancouver

Landes U, Dvir D, Schoels W, Tron C, Ensminger S, Simonato M et al. Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses. EUROINTERVENTION. 2019 May 20;15(1):37-43. https://doi.org/10.4244/EIJ-D-18-00752

Bibtex

@article{13687ec265454325ae487cbd0faf5381,
title = "Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses",
abstract = "AIMS: The aim of this study was to evaluate transcatheter aortic valve-in-valve (ViV) implantation performance in rapid deployment (ViVr) vs. conventional (ViVc) surgical heart valves.METHODS AND RESULTS: A multicentre registry was developed as part of the VIVID international registry. A total of 30 ViVr patients (Perceval, n=24, ATS 3f Enable{\texttrademark}, n=5, and the INTUITY, n=1) were evaluated and compared with 2,288 ViVc patients. Propensity score (PS) matching was performed to adjust further for bias. Compared with ViVc, ViVr patients presented twice as early after surgical heart valve (SHV) implantation (55.2±36.1 vs. 118.4±57.7 months, p<0.001), were more commonly female (82.8% vs. 41.3%, p<0.001), and had shorter body stature and reduced body weight (p<0.05 for both) prior to PS. Implantation was successful in all ViVr cases and, compared with ViVc, was associated with equally favourable haemodynamic outcomes (mean gradient: 14.6±8.3 vs. 16.2±8.9 mmHg, p=0.356; regurgitation ≥mild: 3.7% vs. 5.2%, p=0.793). Periprocedural complication rates were similar and low in both groups. There was no coronary obstruction event in any ViVr case; one patient (3.6%) died during one year of follow-up.CONCLUSIONS: ViVr appears effective, safe and associated with favourable haemodynamic outcome.",
keywords = "Aortic Valve, Aortic Valve Stenosis, Bioprosthesis, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Humans, Prosthesis Design, Treatment Outcome",
author = "Uri Landes and Danny Dvir and Wolfgang Schoels and Christopher Tron and Stephan Ensminger and Matheus Simonato and Ulrich Sch{\"a}fer and Matjaz Bunc and Aldea, {Gabriel S} and Alfredo Cerillo and Stephan Windecker and Antonio Marzocchi and Martin Andreas and Nicolas Amabile and John Webb and Ran Kornowski",
year = "2019",
month = may,
day = "20",
doi = "10.4244/EIJ-D-18-00752",
language = "English",
volume = "15",
pages = "37--43",
journal = "EUROINTERVENTION",
issn = "1774-024X",
publisher = "EUROPA EDITION",
number = "1",

}

RIS

TY - JOUR

T1 - Transcatheter aortic valve-in-valve implantation in degenerative rapid deployment bioprostheses

AU - Landes, Uri

AU - Dvir, Danny

AU - Schoels, Wolfgang

AU - Tron, Christopher

AU - Ensminger, Stephan

AU - Simonato, Matheus

AU - Schäfer, Ulrich

AU - Bunc, Matjaz

AU - Aldea, Gabriel S

AU - Cerillo, Alfredo

AU - Windecker, Stephan

AU - Marzocchi, Antonio

AU - Andreas, Martin

AU - Amabile, Nicolas

AU - Webb, John

AU - Kornowski, Ran

PY - 2019/5/20

Y1 - 2019/5/20

N2 - AIMS: The aim of this study was to evaluate transcatheter aortic valve-in-valve (ViV) implantation performance in rapid deployment (ViVr) vs. conventional (ViVc) surgical heart valves.METHODS AND RESULTS: A multicentre registry was developed as part of the VIVID international registry. A total of 30 ViVr patients (Perceval, n=24, ATS 3f Enable™, n=5, and the INTUITY, n=1) were evaluated and compared with 2,288 ViVc patients. Propensity score (PS) matching was performed to adjust further for bias. Compared with ViVc, ViVr patients presented twice as early after surgical heart valve (SHV) implantation (55.2±36.1 vs. 118.4±57.7 months, p<0.001), were more commonly female (82.8% vs. 41.3%, p<0.001), and had shorter body stature and reduced body weight (p<0.05 for both) prior to PS. Implantation was successful in all ViVr cases and, compared with ViVc, was associated with equally favourable haemodynamic outcomes (mean gradient: 14.6±8.3 vs. 16.2±8.9 mmHg, p=0.356; regurgitation ≥mild: 3.7% vs. 5.2%, p=0.793). Periprocedural complication rates were similar and low in both groups. There was no coronary obstruction event in any ViVr case; one patient (3.6%) died during one year of follow-up.CONCLUSIONS: ViVr appears effective, safe and associated with favourable haemodynamic outcome.

AB - AIMS: The aim of this study was to evaluate transcatheter aortic valve-in-valve (ViV) implantation performance in rapid deployment (ViVr) vs. conventional (ViVc) surgical heart valves.METHODS AND RESULTS: A multicentre registry was developed as part of the VIVID international registry. A total of 30 ViVr patients (Perceval, n=24, ATS 3f Enable™, n=5, and the INTUITY, n=1) were evaluated and compared with 2,288 ViVc patients. Propensity score (PS) matching was performed to adjust further for bias. Compared with ViVc, ViVr patients presented twice as early after surgical heart valve (SHV) implantation (55.2±36.1 vs. 118.4±57.7 months, p<0.001), were more commonly female (82.8% vs. 41.3%, p<0.001), and had shorter body stature and reduced body weight (p<0.05 for both) prior to PS. Implantation was successful in all ViVr cases and, compared with ViVc, was associated with equally favourable haemodynamic outcomes (mean gradient: 14.6±8.3 vs. 16.2±8.9 mmHg, p=0.356; regurgitation ≥mild: 3.7% vs. 5.2%, p=0.793). Periprocedural complication rates were similar and low in both groups. There was no coronary obstruction event in any ViVr case; one patient (3.6%) died during one year of follow-up.CONCLUSIONS: ViVr appears effective, safe and associated with favourable haemodynamic outcome.

KW - Aortic Valve

KW - Aortic Valve Stenosis

KW - Bioprosthesis

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation

KW - Humans

KW - Prosthesis Design

KW - Treatment Outcome

U2 - 10.4244/EIJ-D-18-00752

DO - 10.4244/EIJ-D-18-00752

M3 - SCORING: Journal article

C2 - 30777843

VL - 15

SP - 37

EP - 43

JO - EUROINTERVENTION

JF - EUROINTERVENTION

SN - 1774-024X

IS - 1

ER -